title: Should Xpert® MTB/RIF be rolled out in low-income countries?
authors.forename: Dean
authors.initials: D
authors.lastname: Peters
authors.forename: Grant
authors.initials: G
authors.lastname: Theron
authors.forename: Jonny
authors.initials: J
authors.lastname: Peter
authors.forename: Keertan
authors.initials: K
authors.lastname: Dheda
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology*; D006801:Humans; D021141:Nucleic Acid Amplification Techniques / Q000379:methods*; D012293:Rifampin / Q000494:pharmacology*; D014376:Tuberculosis / Q000175:diagnosis*
chemical_list: D000995:Antitubercular Agents; D012293:Rifampin